Niche Expertise The Drake Institute specializes in non-drug treatments for ADHD and autism with a medical-science driven FullCare program, presenting a premium, center-of-excellence positioning that can be leveraged to cross-sell advanced neurofeedback and QEEG brainmapping services to similar clinics and clinics seeking specialized ADHD/Autism offerings.

Technology Advantage FDA approved QEEG brainmapping and neurofeedback are core to their treatment approach, highlighting opportunities to partner on diagnostic enhancement, data analytics, and scalable brainwave-based treatment protocols for related practices or technology providers seeking field validation.

Expansion Potential With 11-50 employees and a long track record of treating thousands of patients, there may be capacity to explore partnerships for training, licensing, or joint ventures to extend FullCare methodologies to other regions or telehealth-adjacent services.

Market Positioning Positioned as a world-renowned center for ADHD and autism with a comprehensive mind-body approach, the institute can attract referrals from pediatricians, neurologists, and psychologists, offering a gateway for collaborating providers to refer patients for non-drug therapies and neurofeedback programs.

Financial Signals Revenue is reported in a broad range, suggesting potential for growth through expanded service lines, higher-margin neurotechnology offerings, and partnerships that scale patient throughput while maintaining the non-pharmacologic treatment niche.